Basic Info.

Retatrutide — Product Introduction

Retatrutide is an investigational peptide-based therapeutic candidate and a first-in-class triple hormone receptor agonist targeting the GIP, GLP-1, and glucagon receptors.

Retatrutide is being investigated for its potential effects on body weight, glucose metabolism, and overall metabolic health. Clinical research has evaluated its potential applications in obesity, overweight with related health conditions, type 2 diabetes, and other metabolic conditions.  

Key Features
• Active Ingredient: Retatrutide
• Mechanism: GIP / GLP-1 / Glucagon receptor agonist
• Administration studied: Once-weekly subcutaneous injection
• Research areas: Weight management, glucose metabolism, metabolic health
• Development status: Investigational
• Research code: LY3437943

Directions for Use

In clinical studies, retatrutide has been administered as a once-weekly subcutaneous injection. However, the appropriate dose, dose-escalation schedule, injection technique, and treatment duration must be determined according to the applicable clinical-trial protocol or prescribing information from a qualified healthcare professional.  

Do not use or self-administer investigational retatrutide outside an authorized clinical trial or without appropriate medical supervision.

Disclaimer

For research and investigational purposes only. Retatrutide is not currently approved by the FDA or other regulatory agencies for public use. This product information is provided for scientific and educational purposes and is not intended to diagnose, treat, cure, or prevent any disease.